Development of fatal acute liver failure in HIV-HBV coinfected patients

World Journal of Gastroenterology

Volumn 16, Issue 32, 2010, Pages 4107-4111

  Anderson, Albert M ^a   Mosunjac, Marina B ^a   Palmore, Melody P ^a   Osborn, Melissa K ^a   Muir, Andrew J ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis B virus; Human immunodeficiency virus; Liver failure

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; EMTRICITABINE; FOSAMPRENAVIR; LAMIVUDINE; RITONAVIR; TENOFOVIR;

ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LIVER BIOPSY; LIVER FAILURE; LIVER TOXICITY; MALE; MIXED INFECTION;

EID: 77956637215     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i32.4107     Document Type: Article

References (28)

1. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601
2. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liverrelated mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926
3. Rouet F, Chaix ML, Inwoley A, Anaky MF, Fassinou P, Kpozehouen A, Rouzioux C, Blanche S, Msellati P. Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children. Clin Infect Dis 2008; 46: 361-366
4. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, Marcellin P. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29: 1306-1310
5. Puoti M, Airoldi M, Bruno R, Zanini B, Spinetti A, Pezzoli C, Patroni A, Castelli F, Sacchi P, Filice G, Carosi G. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev 2002; 4: 27-35
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda: Department of Health and Human Services. December 1, 2009
7. Cooper CL. HIV antiretroviral medications and hepatotoxicity. Curr Opin HIV AIDS 2007; 2: 466-473
8. Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis 2003; 23: 183-194
9. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23-31
10. Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, Gathe JC Jr, Visnegarwala F, Trautner BW. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81: 213-227
11. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14: 2895-2902
12. Vogel M, Rockstroh JK. Hepatotoxicity and liver disease in the context of HIV therapy. Curr Opin HIV AIDS 2007; 2: 306-313
13. Ofotokun I, Smithson SE, Lu C, Easley KA, Lennox JL. Liver enzymes elevation and immune reconstitution among treatment- naïve HIV-infected patients instituting antiretroviral therapy. Am J Med Sci 2007; 334: 334-341
14. Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, Spinetti A, Putzolu V, Casari S, Tomasoni L, Quiros-Roldan E, Favret M, Berchich L, Grigolato P, Callea F, Carosi G. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003; 32: 259-267
15. Clark SJ, Creighton S, Portmann B, Taylor C, Wendon JA, Cramp ME. Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases. J Hepatol 2002; 36: 295-301
16. Watanabe S, Deguchi A, Uchida N, Kurokohchi K, Arima K, Nishioka M, Hasui H. Histopathologic comparison of antimitochondrial antibody-positive primary biliary cirrhosis and autoimmune cholangiopathy. Hepatol Res 2001; 19: 41-51
17. Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis 2009; 29: 364-372
18. Sagnelli E, Manzillo G, Maio G, Pasquale G, Felaco FM, Filippini P, Izzo CM, Piccinino F. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 1980; 2: 395-397
19. Lesho E. Evidence base for using corticosteroids to treat HIV associated immune reconstitution syndrome. Expert Rev Anti Infect Ther 2006; 4: 469-478
20. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41: 1179-1197
21. Nüesch R, Ananworanich J, Srasuebkul P, Chetchotisakd P, Prasithsirikul W, Klinbuayam W, Mahanontharit A, Jupimai T, Ruxrungtham K, Hirschel B. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS 2008; 22: 152-154
22. Crane M, Matthews G, Lewin SR. Hepatitis virus immune restoration disease of the liver. Curr Opin HIV AIDS 2008; 3: 446-452
23. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455
24. Sasadeusz J, Audsley J, Mijch A, Baden R, Caro J, Hunter H, Matthews G, McMahon MA, Olender SA, Siliciano RF, Lewin SR, Thio CL. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS 2008; 22: 947-955
25. Low E, Cox A, Atkins M, Nelson M. Telbivudine has activity against HIV. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8-11; Montreal, Canada
26. Tateo M, Roque-Afonso AM, Antonini TM, Medja F, Lombes A, Jardel C, Teicher E, Sebagh M, Roche B, Castaing D, Samuel D, Duclos-Vallee JC. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009; 23: 1069-1076
27. Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, Rodriguez-Novoa S, Alvarez E, Jimenez-Nacher I, Soriano V. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2010; 65: 543-547
28. Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, Oleske JM, Currier JS, Gallant JE. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 651-681